Lipid-lowering treatment modifications among patients with hyperlipidemia and a prior cardiovascular event: a US retrospective cohort study

References

• Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics – 2010 update: a report from the American Heart Association. Circulation. 2010;121:e46-215
   PubMed Web of Science ®Google Scholar
• Nichols GA, Bell TJ, Pedula KL, et al. Medical care costs among patients with established cardiovascular disease. Am J Manag Care 2010;16:e86-93
   PubMed Web of Science ®Google Scholar
• Pharmaceutical Research and Manufacturers of America. From hope to cure: fighting high cholesterol. Available at: http://www.fromhopetocures.org/infographic/fighting-high-cholesterol-infographic [Last accessed 18 February 2016]
   Google Scholar
• Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 2005;366:1267-78
   PubMed Web of Science ®Google Scholar
• Delahoy PJ, Magliano DJ, Webb K, et al. The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis. Clin Ther 2009;31:236-44
   PubMed Web of Science ®Google Scholar
• Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low-density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423-7
   PubMed Web of Science ®Google Scholar
• Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lipid-lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomized trials. Lancet 2010;376:1670-81
   PubMed Web of Science ®Google Scholar
• Catapano AL, Reiner Z, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias. Atherosclerosis 2011;217:3-46
   PubMed Web of Science ®Google Scholar
• Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations. Can J Cardiol 2009;25:567-79
   Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004;44:720-32
   PubMed Web of Science ®Google Scholar
• Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation 2006;113:2363-72
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129(Suppl 2):S1-S45
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program Expert Panel. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97
   PubMed Web of Science ®Google Scholar
• Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387-97
   PubMed Web of Science ®Google Scholar
• EUROASPIRE III and Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 2001;357:995-1001
   PubMed Web of Science ®Google Scholar
• Pearson TA, Laurora I, Chu H, et al. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-67
   PubMed Web of Science ®Google Scholar
• Toth PP, Foody JM, Tomassini JE, et al. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease. J Clin Lipidol 2014;8:107-16
   PubMed Web of Science ®Google Scholar
• Aronow HD, Hess G, Hill J, et al. Switching from atorvastatin to simvastatin in patients at high cardiovascular risk: effects on low-density lipoprotein cholesterol. Am J Ther 2010;17:167-75
   PubMed Web of Science ®Google Scholar
• Atar D, Carmena R, Clemmensen P, et al. Clinical review: impact of statin substitution policies on patient outcomes. Ann Med 2009;41:242-56
   PubMed Web of Science ®Google Scholar
• Rublee DA, Burke JP. LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice. Postgrad Med 2010;122:16-24
   PubMed Web of Science ®Google Scholar
• Willey VJ, Bullano MF, Shoetan NN, et al. Therapy modifications and low-density lipoprotein cholesterol goal attainment rates associated with the initiation of generic simvastatin. Curr Med Res Opin 2010;26:121-8
   PubMed Web of Science ®Google Scholar
• Bermingham M, Hayden J, Dawkins I, et al. Prospective analysis of LDL-C goal achievement and self-reported medication adherence among statin users in primary care. Clin Ther 2011;33:1180-9
   PubMed Web of Science ®Google Scholar
• Kon RH, Russo MW, Ory B, et al. Misperception among physicians and patients regarding the risks and benefits of statin treatment: the potential role of direct-to-consumer advertising. J Clin Lipidol 2008;2:51-7
   PubMed Web of Science ®Google Scholar
• Berthold H, Gouni-Berthold I. Lipid-lowering drug therapy in elderly patients. Curr Pharm Des 2011;17:877-93
   PubMed Web of Science ®Google Scholar
• Quek RGW, Fox KM, Wang L, et al. A US claims-based analysis of real-world lipid-lowering treatment patterns in patients with high cardiovascular disease risk or a previous coronary event. Am J Cardiol 2016;117:495-500
   PubMed Web of Science ®Google Scholar
• Kastelein JJP, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431-43
   PubMed Web of Science ®Google Scholar
• Foody JM, Joyce AT, Rudolph AE, et al. Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a US managed care study. Curr Med Res Opin 2008;24:1987-2000
   PubMed Web of Science ®Google Scholar
• Nichols GA, Nag S, Chan W. Intensity of lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment among the elderly before and after the 2004 National Cholesterol Education Program Adult Treatment Panel III update. Am Heart J 2007;154:554-60
   PubMed Web of Science ®Google Scholar